This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Harvard Bioscience Files Two Major Patents In Field Of Regenerative Medicine

HOLLISTON, Mass., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. ("Harvard Bioscience," or the "Company") (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, has filed two major patents in the field of regenerative medicine, the first covering 61 claims for its stem cell therapy injectors and the second for 338 claims for bioreactors for organ growth.

David Green, President of Harvard Bioscience, commented, "This is an important milestone for Harvard Bioscience illustrating the value we place on our intellectual property in the emerging field of regenerative medicine. Our strategy is to supply tools to researchers and clinicians within the field of regenerative medicine, and completing these patent filings marks an important milestone in that plan."

Harvard Bioscience is collaborating with leading academics in the field of regenerative medicine to develop its regenerative medicine products. In 2009, the Company licensed the bioreactor technology underlying the world's first human transplant of a regenerated bronchus. The transplant was performed by Dr. Paolo Macchiarini at the Department of General Thoracic Surgery, Hospital Clinic, Barcelona, Spain and the work was published in The Lancet on November 19, 2008. This "InBreath" bioreactor is now commercially available. In 2010, the Company's Harvard Apparatus / Hugo Sachs Elektronik business collaborated with Dr. Harald Ott and Massachusetts General Hospital to design and manufacture a novel bioreactor that was used to grow a functional lung that was transplanted into a rat. The research was published online in Nature Medicine on July 13, 2010.

In addition to developing bioreactors, Harvard Bioscience is also developing a stem cell therapy injector based on its market leading Harvard Apparatus research syringe pump technology. The Company expects to submit this injector to the US FDA next year for approval for clinical use on patients.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs